Clinical Trials · NCT04771273
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 295
- Start date
- Apr 2021
- Locations
- 154 sites, 25 countries
- Primary endpoint
- Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment